Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Department of Cancer Stem Cell Research, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Front Immunol. 2021 Jul 21;12:713225. doi: 10.3389/fimmu.2021.713225. eCollection 2021.
CD226, an activating receptor expressed on the surface of natural killer (NK) cells and T cells, is also seen on B cells and CD226 polymorphism is associated with systemic lupus erythematosus (SLE). Because the specific roles of CD226 B cells in SLE are still unknown, we investigated the association of CD226 B cells with SLE.
We measured CD226 expression on B cells and its subsets using flow cytometry in 48 SLE patients and 24 healthy controls (HCs). We assessed the relationships between CD226 B cells and SLE Disease Activity Index 2000 (SLEDAI-2K), clinical manifestations, laboratory data, and prognosis after 12 months.
The proportions of CD226 cells in whole B cells and all its subsets were significantly higher in SLE patients than HCs. In SLE patients, the proportions of CD226 B cells and CD226 switched-memory (SM) B cells were significantly correlated with SLEDAI-2K scores and anti-dsDNA antibody titers, and negatively correlated with serum complement levels. Moreover, basal percentages of CD226 B cells and CD226 SM B cells were low in patients who were in Lupus Low Disease Activity State after 12 months. In patients with renal involvement, the proportion of CD226 B cells increased. Additionally, the proportion of CD226 B cells was higher in patients who were not in complete renal remission after 12 months.
Increased proportion of CD226 B cells was associated with disease activity and prognosis of SLE. CD226 B cells may be a useful biomarker for the management of SLE.
CD226 是一种表达在自然杀伤 (NK) 细胞和 T 细胞表面的激活受体，也存在于 B 细胞上，CD226 多态性与系统性红斑狼疮 (SLE) 有关。由于 CD226 B 细胞在 SLE 中的具体作用尚不清楚，我们研究了 CD226 B 细胞与 SLE 的关系。
我们使用流式细胞术测量了 48 例 SLE 患者和 24 例健康对照者 (HCs) 中 B 细胞及其亚群上的 CD226 表达。我们评估了 CD226 B 细胞与 SLE 疾病活动指数 2000 (SLEDAI-2K)、临床表现、实验室数据以及 12 个月后的预后之间的关系。
SLE 患者全 B 细胞和所有亚群中 CD226 细胞的比例明显高于 HCs。在 SLE 患者中，CD226 B 细胞和 CD226 转换型记忆 (SM) B 细胞的比例与 SLEDAI-2K 评分和抗 dsDNA 抗体滴度显著相关，与血清补体水平呈负相关。此外，在 12 个月后处于狼疮低疾病活动状态的患者中，CD226 B 细胞和 CD226 SM B 细胞的基础比例较低。在有肾脏受累的患者中，CD226 B 细胞的比例增加。此外，在 12 个月后未达到完全肾脏缓解的患者中，CD226 B 细胞的比例较高。
CD226 B 细胞比例增加与 SLE 的疾病活动度和预后相关。CD226 B 细胞可能是 SLE 管理的有用生物标志物。
